Drug Trial Radar · NCT06218914
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Mar 22, 2024
Primary completion
Aug 30, 2027
Study completion Nov 18, 2043
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Conditions
- Non-small Cell Lung Cancer
- Colorectal Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Endometrial Cancer
- Solid Tumor, Adult
- KRAS G12D
Interventions
NT-112: Autologous, engineered T Cells targeting KRAS G12DBiological
NT-112 targets KRAS G12D in the context of HLA-C\*08:02
AZD0240: Autologous, engineered T Cells targeting KRAS G12DBiological
AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumorsTime frame: Through study completion, an average of 2 years
- Part A (Dose Escalation): Evaluate MTD and recommended dose for expansion (RDE)Time frame: 28 days after infusion
- Part B (Expansion): Further evaluate the safety of KRAS TCRTs at the RDE in subjects with unresectable, advanced, and/or metastatic solid tumorsTime frame: 28 days after infusion
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Jacksonville, Florida
Research Site
Chicago, Illinois
Research Site
Westwood, Kansas
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.